Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531687 | 1.00 | P2RX7 (0.47) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL26521363 | 0.87 | NOTUM (0.49) | P2RX7KDM4ENOTUMIDH1IDH2 | |
| SCHEMBL1256422 | 0.85 | P2RX7 (0.49) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL22828437 | 0.82 | NOS3 (0.46) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL3295150 | 0.82 | P2RX7 (0.50) | P2RX7NOTUMIDH1IDH2GABRA1 | |
| Hydrochloric Acid SCHEMBL23649640 | 0.80 | NOS3 (0.45) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL22658701 | 0.79 | NOS3 (0.43) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL29433487 | 0.79 | NOS3 (0.43) | P2RX7NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL30695913 | 0.76 | NOS2 (0.50) | NOS3NOS2KDM4EIDH1HSD17B10 | |
| SCHEMBL77583 | 0.76 | NOS2 (0.50) | NOS3NOS2KDM4EIDH1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866512-A | A kind of preparation method of the trifluoromethyl pyridine of 2 hydroxyl 6 | 常州沃腾化工科技有限公司 | 2017-06-20 | — | — | CN | claimed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-2081905-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-29 | — | — | EP | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | claimed |
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| CN-121824414-A | Production method of 2-amino-6- (trifluoromethyl) pyridine | 苏州艾缇克药物化学有限公司 | 2026-04-10 | — | — | CN | disclosed |
| US-5464781-A | TREATING RHEUMATIC DISEASES | THE BOOTS COMPANY PLC (GB) | 1995-11-07 | — | — | US | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0618916-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013097-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | P2RX7 214/4885NOS3 3408/4885NOS2 3125/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | P2RX7 1117/4885NOS3 187/4885NOS2 294/4885 |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | P2RX7 51/4885NOS3 2847/4885NOS2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.